Agency Information Collection Activities; Proposed Collection; Comment Request; Importer's Entry Notice, 70951-70953 [2013-28438]
Download as PDF
Federal Register / Vol. 78, No. 229 / Wednesday, November 27, 2013 / Notices
such entities. Typical respondents are
non-profit community based
organizations who are reporting on the
youth that they serve through their
70951
Basic Center, Transitional Living and
Street Outreach programs.
ANNUAL BURDEN ESTIMATES
Youth Profile: BCP Entrance Report ...............................................
Youth Profile: TLP Entrance Report ................................................
Youth Profile: BCP Exit Report .......................................................
Youth Profile: TLP Exit Report ........................................................
Brief Contacts ..................................................................................
BCP Turn-a-ways ............................................................................
TLP Turn-a-ways .............................................................................
Street Outreach Report ...................................................................
Data Transfer ...................................................................................
Estimated Total Annual Burden
Hours: 31, 441.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Planning, Research and Evaluation, 370
L’Enfant Promenade SW., Washington,
DC 20447, Attn: ACF Reports Clearance
Officer. All requests should be
identified by the title of the information
collection. Email address:
infocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Email: OIRA_
SUBMISSION@OMB.EOP.GOV. Attn:
Desk Officer for the Administration for
Children and Families
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2013–28430 Filed 11–26–13; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
emcdonald on DSK67QTVN1PROD with NOTICES
[Docket No. FDA–2013–N–1423]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Importer’s Entry
Notice
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
VerDate Mar<15>2010
17:02 Nov 26, 2013
Jkt 232001
Number of responses per respondent
Number of respondents
Instrument
321
205
321
205
526
321
205
138
664
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
FDA’s Importer’s Entry Notice.
DATES: Submit either electronic or
written comments on the collection of
information by January 27, 2014.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 1350 Piccard
Dr., PI50–400B, Rockville, MD 20850,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
SUMMARY:
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Average burden
hours per response
118
19
118
19
153
9
24
5,660
2
.125
.125
.125
.125
.05
.05
.05
.02
.50
Total burden
hours
4, 735
487
4,735
487
4, 024
144
246
15,622
664
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Information Request Regarding
Importer’s Entry Notice—(OMB Control
Number 0910–0046)—Extension
Section 801 of the Federal Food, Drug,
and Cosmetic Act (the FD&C Act)
(U.S.C. 381) charges the Secretary of
Health and Human Services (HHS),
through FDA, with the responsibility of
assuring foreign origin FDA regulated
foods, drugs, cosmetics, medical
devices, radiological health, and tobacco
products offered for import into the
United States meet the same
requirements of the FD&C Act as do
domestic products, and for preventing
products from entering the country if
they are not in compliance. The
discharge of this responsibility involves
close coordination and cooperation
E:\FR\FM\27NON1.SGM
27NON1
70952
Federal Register / Vol. 78, No. 229 / Wednesday, November 27, 2013 / Notices
between FDA headquarters and field
inspectional personnel and the U.S.
Customs Service (USCS), as the USCS is
responsible for enforcing the revenue
laws covering the very same products.
This collection of information gathers
data for FDA-regulated products being
imported into the United States and is
being used by FDA to review and
prevent imported products from
entering the United States if the
products do not meet the same
requirements of the FD&C Act as
domestic products.
Until October 1995, importers were
required to file manual entries on OMBapproved forms which were
accompanied by related documents.
FDA did away with use of the paper
forms effective October 1, 1995, to
eliminate duplicity of information and
to reduce the paperwork burden both on
the import community and FDA. FDA
then implemented an automated
nationwide entry processing system
which enabled FDA to more efficiently
obtain and process the information it
requires to fulfill its regulatory
responsibility.
Most of the information FDA requires
to carry out its regulatory
responsibilities under section 801 is
already provided electronically by filers
to USCS. Because USCS relays this data
to FDA using an electronic interface, the
majority of data submitted by the entry
filer need be completed only once.
At each U.S. port of entry (seaport,
landport, and airport) where foreignorigin, FDA-regulated products are
offered for import, FDA is notified
through USCS’s Automated Commercial
System (ACS) by the importer (or his/
her agent) of the arrival of each entry.
Following such notification, FDA
reviews relevant data to ensure the
imported product meets the standards
as required for domestic products,
decides on the admissibility of the
imported product, and informs the
importer and USCS of its decision. A
single entry frequently contains
multiple lines of different products.
FDA may authorize products listed on
specific lines to enter the United States
unimpeded, while other products listed
in the same entry may be held pending
further FDA review/action.
All entry data pass through a
screening criteria program resident on a
USCS computer. This screening
program was developed and is
maintained by FDA. This electronic
screening criteria module makes the
initial screening decision on every entry
of foreign-origin, FDA-regulated
product. Almost instantaneously after
the entry is filed, the filer receives
FDA’s admissibility decision for each
entry, i.e., ‘‘MAY PROCEED’’ or ‘‘FDA
REVIEW.’’
In addition to the information
collected by USCS, FDA requires four
additional pieces of information that
were not available from USCS’s system
in order to make an admissibility
decision for each entry. These data
elements include the FDA Product
Code, FDA country of production,
manufacturer/shipper, and ultimate
consignee. OMB has previously
approved the automated collection of
these four data elements for tobacco
products that filers could provide to
FDA along with other entry-related
information. Providing this information
to FDA results in importers receiving an
FDA admissibility decision more
expeditiously, e.g., the quantity, value,
and Affirmation(s) of Compliance with
Qualifier(s).
Since the inception of the interface
with ACS, FDA’s electronic screening
criteria program has been applied
nationwide. This eliminates issues such
as ‘‘port shopping’’ (attempts to
intentionally slip products through one
FDA port when refused by another, or
filing entries at a port known to receive
a high volume of entries). Every
electronically submitted entry line of
foreign-origin, FDA-regulated product
undergoes automated screening and the
screening criteria can be set to be as
specific or as broad as applicable;
changes are immediately effective. This
capability is of tremendous value in
protecting the public if there is a need
to immediately halt specific product
from entering the United States.
If the data in this collection of
information is not collected, FDA could
not adequately meet its statutory
responsibilities to regulate imported
products, nor control potentially
dangerous products from entering the
U.S. marketplace.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
FDA Imported Products
Number of
responses per
respondent
Non-Tobacco ..............................................
3,406
1,089
3,709,134
Tobacco ......................................................
330
68
Total .....................................................
........................
............................
emcdonald on DSK67QTVN1PROD with NOTICES
1 There
Average
burden
per response
Total annual
responses
Total hours
519,279
22,440
.14 .......................................
(8 minutes)
.14 .......................................
(8 minutes)
........................
.............................................
522,421
3142
are no capital costs or operating and maintenance costs associated with this collection of information.
The hourly burden for this
information collection is based on
FDA’s averaging of data obtained during
a survey of nine representative filers
nationwide and FDA’s experience. For
purposes of comparison of hourly
burden, the filers also were requested to
provide the same information with
regard to filing entries manually. FDA
felt that the average time for completing
either electronic or manual entries was
very similar.
Based on data collected by FDA’s
survey of nine filers and its experience,
VerDate Mar<15>2010
17:02 Nov 26, 2013
Jkt 232001
the total annual burden to the import
community to submit information
electronically for 3,731,574 average
annual responses was 522,421 hours.
The previously OMB-approved hours
per response (0.14 hours) are expected
to remain the same.
This burden includes the time FDA
estimates it will take respondents to
compile and provide documents to FDA
for those entries where FDA cannot
make an admissibility decision based on
the electronic data alone. Based on the
survey of nine filers and FDA’s past
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
experience, FDA estimates that there
will be no additional costs to provide
import data electronically to FDA, as
filers already have equipment and
software in place to enable them to
provide data to USCS via the automated
system. Therefore, no additional
software or hardware need be developed
or purchased to enable filers to file the
FDA data elements at the same time
they file entries electronically with
USCS.
E:\FR\FM\27NON1.SGM
27NON1
Federal Register / Vol. 78, No. 229 / Wednesday, November 27, 2013 / Notices
Dated: November 18, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
November 12, 2013, to provide
comments. The Agency is reopening the
comment period until December 11,
2013 to allow interested persons
additional time to submit comments.
[FR Doc. 2013–28438 Filed 11–26–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2007–D–0369]
Draft Guidance for Industry on
Bioequivalence Recommendations for
Fluticasone Propionate; Salmeterol
Xinafoate; Reopening of the Comment
Period
AGENCY:
Food and Drug Administration,
HHS.
Notice; reopening of the
comment period.
ACTION:
The Food and Drug
Administration (FDA) is reopening the
comment period for the notice of
availability entitled ‘‘Draft Guidance for
Industry on Bioequivalence
Recommendations for Fluticasone
Propionate; Salmeterol Xinafoate’’,
published in the Federal Register of
September 10, 2013 (78 FR 55263). In
that notice, FDA requested public
comment on the draft guidance. FDA is
reopening the comment period due to
the inability of some commenters to
submit comments through the
www.regulations.gov Web site from
November 4, 2013, through November
13, 2013, due to technical difficulties.
DATES: Submit either electronic or
written comments to the docket by
December 11, 2013.
ADDRESSES: Submit electronic
comments to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Bhawana Saluja, Center for Drug
Evaluation and Research (HFD–643),
Food and Drug Administration, 7519
Standish Pl., Rockville, MD 20855, 240–
276–8465.
SUPPLEMENTARY INFORMATION:
SUMMARY:
emcdonald on DSK67QTVN1PROD with NOTICES
I. Background
In the Federal Register of September
10, 2013 (78 FR 55263), FDA announced
the notice of availability for the draft
guidance entitled ‘‘Draft Guidance for
Industry on Bioequivalence
Recommendations for Fluticasone
Propionate; Salmeterol Xinafoate.’’
Interested persons were given until
VerDate Mar<15>2010
17:02 Nov 26, 2013
Jkt 232001
II. Request for Comments
Following publication of the
September 10, 2013, notice of
availability, there were technical
difficulties with the
www.regulations.gov Web site from
November 4, 2013, through November
13, 2013, which would have prevented
comments from being submitted.
III. How To Submit Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
Dated: November 20, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–28394 Filed 11–26–13; 8:45 am]
BILLING CODE 4160–01–P
70953
November 13, 2013, due to technical
difficulties.
Submit either electronic or
written comments to the docket by
December 11, 2013.
ADDRESSES: Submit electronic
comments to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Jaewon Hong, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10001 New
Hampshire Ave., rm. 4145, Silver
Spring, MD 20993–0002, 301–796–6707,
email: askGDUFA@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
DATES:
I. Background
In the Federal Register of September
10, 2013 (78 FR 55261), FDA announced
the notice of availability for the draft
guidance entitled ‘‘Draft Guidance for
Industry on Generic Drug User Fee
Amendments of 2012: Questions and
Answers (Revision 1).’’ Interested
persons were given until November 12,
2013, to provide comments. The Agency
is reopening the comment period until
December 11, 2013 to allow interested
persons additional time to submit
comments.
II. Requests for Comments
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–D–0880]
Draft Guidance for Industry on Generic
Drug User Fee Amendments of 2012:
Questions and Answers (Revision 1);
Reopening of the Comment Period
AGENCY:
Food and Drug Administration,
HHS.
Notice; reopening of the
comment period.
ACTION:
The Food and Drug
Administration (FDA) is reopening the
comment period for the notice of
availability entitled ‘‘Draft Guidance for
Industry on Generic Drug User Fee
Amendments of 2012: Questions and
Answers (Revision 1)’’, published in the
Federal Register of September 10, 2013
(78 FR 55261). In that notice, FDA
requested public comment on the draft
guidance. FDA is reopening the
comment period due to the inability of
some commenters to submit comments
through the www.regulations.gov Web
site from November 4, 2013, through
SUMMARY:
PO 00000
Frm 00039
Fmt 4703
Sfmt 9990
Following publication of the
September 10, 2013, notice of
availability, there were technical
difficulties with the
www.regulations.gov Web site from
November 4, 2013, through November
13, 2013, which would have prevented
comments from being submitted.
III. How To Submit Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
Dated: November 20, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–28392 Filed 11–26–13; 8:45 am]
BILLING CODE 4160–01–P
E:\FR\FM\27NON1.SGM
27NON1
Agencies
[Federal Register Volume 78, Number 229 (Wednesday, November 27, 2013)]
[Notices]
[Pages 70951-70953]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-28438]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-1423]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Importer's Entry Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on FDA's Importer's Entry Notice.
DATES: Submit either electronic or written comments on the collection
of information by January 27, 2014.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville,
MD 20850, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Information Request Regarding Importer's Entry Notice--(OMB Control
Number 0910-0046)--Extension
Section 801 of the Federal Food, Drug, and Cosmetic Act (the FD&C
Act) (U.S.C. 381) charges the Secretary of Health and Human Services
(HHS), through FDA, with the responsibility of assuring foreign origin
FDA regulated foods, drugs, cosmetics, medical devices, radiological
health, and tobacco products offered for import into the United States
meet the same requirements of the FD&C Act as do domestic products, and
for preventing products from entering the country if they are not in
compliance. The discharge of this responsibility involves close
coordination and cooperation
[[Page 70952]]
between FDA headquarters and field inspectional personnel and the U.S.
Customs Service (USCS), as the USCS is responsible for enforcing the
revenue laws covering the very same products.
This collection of information gathers data for FDA-regulated
products being imported into the United States and is being used by FDA
to review and prevent imported products from entering the United States
if the products do not meet the same requirements of the FD&C Act as
domestic products.
Until October 1995, importers were required to file manual entries
on OMB-approved forms which were accompanied by related documents. FDA
did away with use of the paper forms effective October 1, 1995, to
eliminate duplicity of information and to reduce the paperwork burden
both on the import community and FDA. FDA then implemented an automated
nationwide entry processing system which enabled FDA to more
efficiently obtain and process the information it requires to fulfill
its regulatory responsibility.
Most of the information FDA requires to carry out its regulatory
responsibilities under section 801 is already provided electronically
by filers to USCS. Because USCS relays this data to FDA using an
electronic interface, the majority of data submitted by the entry filer
need be completed only once.
At each U.S. port of entry (seaport, landport, and airport) where
foreign-origin, FDA-regulated products are offered for import, FDA is
notified through USCS's Automated Commercial System (ACS) by the
importer (or his/her agent) of the arrival of each entry. Following
such notification, FDA reviews relevant data to ensure the imported
product meets the standards as required for domestic products, decides
on the admissibility of the imported product, and informs the importer
and USCS of its decision. A single entry frequently contains multiple
lines of different products. FDA may authorize products listed on
specific lines to enter the United States unimpeded, while other
products listed in the same entry may be held pending further FDA
review/action.
All entry data pass through a screening criteria program resident
on a USCS computer. This screening program was developed and is
maintained by FDA. This electronic screening criteria module makes the
initial screening decision on every entry of foreign-origin, FDA-
regulated product. Almost instantaneously after the entry is filed, the
filer receives FDA's admissibility decision for each entry, i.e., ``MAY
PROCEED'' or ``FDA REVIEW.''
In addition to the information collected by USCS, FDA requires four
additional pieces of information that were not available from USCS's
system in order to make an admissibility decision for each entry. These
data elements include the FDA Product Code, FDA country of production,
manufacturer/shipper, and ultimate consignee. OMB has previously
approved the automated collection of these four data elements for
tobacco products that filers could provide to FDA along with other
entry-related information. Providing this information to FDA results in
importers receiving an FDA admissibility decision more expeditiously,
e.g., the quantity, value, and Affirmation(s) of Compliance with
Qualifier(s).
Since the inception of the interface with ACS, FDA's electronic
screening criteria program has been applied nationwide. This eliminates
issues such as ``port shopping'' (attempts to intentionally slip
products through one FDA port when refused by another, or filing
entries at a port known to receive a high volume of entries). Every
electronically submitted entry line of foreign-origin, FDA-regulated
product undergoes automated screening and the screening criteria can be
set to be as specific or as broad as applicable; changes are
immediately effective. This capability is of tremendous value in
protecting the public if there is a need to immediately halt specific
product from entering the United States.
If the data in this collection of information is not collected, FDA
could not adequately meet its statutory responsibilities to regulate
imported products, nor control potentially dangerous products from
entering the U.S. marketplace.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
FDA Imported Products Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
Non-Tobacco.................. 3,406 1,089 3,709,134 .14............ 519,279
(8 minutes)....
Tobacco...................... 330 68 22,440 .14............ 3142
(8 minutes)....
----------------------------------------------------------------------------------
Total.................... .............. ................ .............. ............... 522,421
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
The hourly burden for this information collection is based on FDA's
averaging of data obtained during a survey of nine representative
filers nationwide and FDA's experience. For purposes of comparison of
hourly burden, the filers also were requested to provide the same
information with regard to filing entries manually. FDA felt that the
average time for completing either electronic or manual entries was
very similar.
Based on data collected by FDA's survey of nine filers and its
experience, the total annual burden to the import community to submit
information electronically for 3,731,574 average annual responses was
522,421 hours. The previously OMB-approved hours per response (0.14
hours) are expected to remain the same.
This burden includes the time FDA estimates it will take
respondents to compile and provide documents to FDA for those entries
where FDA cannot make an admissibility decision based on the electronic
data alone. Based on the survey of nine filers and FDA's past
experience, FDA estimates that there will be no additional costs to
provide import data electronically to FDA, as filers already have
equipment and software in place to enable them to provide data to USCS
via the automated system. Therefore, no additional software or hardware
need be developed or purchased to enable filers to file the FDA data
elements at the same time they file entries electronically with USCS.
[[Page 70953]]
Dated: November 18, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-28438 Filed 11-26-13; 8:45 am]
BILLING CODE 4160-01-P